S. Brugnara

448 total citations
19 papers, 315 citations indexed

About

S. Brugnara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, S. Brugnara has authored 19 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in S. Brugnara's work include Melanoma and MAPK Pathways (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Glioma Diagnosis and Treatment (3 papers). S. Brugnara is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Glioma Diagnosis and Treatment (3 papers). S. Brugnara collaborates with scholars based in Italy and United States. S. Brugnara's co-authors include Enzo Galligioni, Michele Guida, Antonella Romanini, Vanna Chiarion‐Sileni, Ruggero Ridolfi, Orazio Caffo, Mattia Barbareschi, Laura Ridolfi, Manuela Gariboldi and D Aldovini and has published in prestigious journals such as Journal of Clinical Oncology, Neuroscience and British Journal of Cancer.

In The Last Decade

S. Brugnara

15 papers receiving 305 citations

Peers

Countries citing papers authored by S. Brugnara

Since Specialization

Citations

This map shows the geographic impact of S. Brugnara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Brugnara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Brugnara more than expected).

Fields of papers citing papers by S. Brugnara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Brugnara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Brugnara. The network helps show where S. Brugnara may publish in the future.

Co-authorship network of co-authors of S. Brugnara

This figure shows the co-authorship network connecting the top 25 collaborators of S. Brugnara. A scholar is included among the top collaborators of S. Brugnara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Brugnara. S. Brugnara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma 2025 ·Cell Death Discovery ·(unknown), Yari Ciribilli, S. Brugnara, (unknown), (unknown), (unknown), (unknown), (unknown), Carlo Mosci, Ulrich Pfeffer, Adriana Amaro, Paola Monti, Alessandra Bisio	0
2	Using Single-Cell RNA sequencing with Drosophila, Zebrafish, and mouse models for studying Alzheimer’s and Parkinson’s disease 2025 ·Neuroscience ·(unknown), (unknown), S. Brugnara, (unknown), Silvana Savino, (unknown), (unknown), (unknown), Paola Bellosta, Michael Carl, Lucia Poggi, Giovanni Provenzano	1
3	507MO REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients 2023 ·Annals of Oncology ·Giuseppe Lombardi, Isacco Desideri, Veronica Villani, Matteo Simonelli, Michela Buglione, (unknown), Enrico Franceschi, Paola Gaviani, I. Stasi, Claudia Caserta, S. Brugnara, Ivan Lolli, (unknown), Paola Bini, (unknown), Silvia Scoccianti, Giovanna Magni, Mario Caccese, Gian Luca De Salvo, Vittorina Zagonel	1
4	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study 2021 ·ESMO Open ·Michele Guida, Sabino Strippoli, Milena Maule, Pietro Quaglino, (unknown), (unknown), (unknown), Paola Queirolo, Laura Ridolfi, (unknown), Emilia Cocorocchio, Anna Maria Di Giacomo, Lucia Festino, Barbara Merelli, Marcella Occelli, S. Brugnara, Alessandro Marco Minisini, (unknown), Stella Tommasi, Simona De Summa	35
5	Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report 2019 ·Drugs in Context ·S. Brugnara, (unknown), (unknown), Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo	4
6	Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation 2018 ·Drugs in Context ·S. Brugnara, (unknown), (unknown), Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo	9
7	P01.084 Re-irradiation in recurrent glioblastoma: proton therapy with or without chemotherapy 2018 ·Neuro-Oncology ·Dante Amelio, Daniele Scartoni, Paolo Farace, L. Widesott, Sabina Vennarini, F. Fellin, S. Brugnara, (unknown), Marco Schwarz, Maurizio Amichetti	1
8	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer 2017 ·Anti-Cancer Drugs ·(unknown), Viviana Murgia, Antonello Veccia, S. Brugnara, A. Caldara, Antonella Ferro, M. Frisinghelli, Francesca Maines, Chiara Trentin, F. Valduga, Orazio Caffo	1
9	Proton Therapy Reirradiation in Difficult-to-Treat Recurrent Glioblastoma 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Dante Amelio, Daniele Scartoni, Paolo Farace, L. Widesott, Stefano Lorentini, Sabina Vennarini, F. Fellin, S. Brugnara, Francesca Maines, Michael Schwarz, Maurizio Amichetti	0
10	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma 2016 ·Journal of Thoracic Oncology ·Mirko Marabese, Elisa Caiola, Marina Chiara Garassino, Giulio Rastelli, (unknown), S. Brugnara, Massimo Broggini, Monica Ganzinelli	5
11	Concurrent chemoradiotherapy (cCTRT) with weekly cisplatin (wCDDP) in locally advanced cervical cancer (LACC) patients (pts): a monoinstitutional experience 2015 ·Annals of Oncology ·Viviana Murgia, Orazio Caffo, A. Caldara, S. Brugnara, (unknown), Antonella Ferro, M. Frisinghelli, (unknown), Francesca Maines, (unknown), Chiara Trentin, F. Valduga, Antonello Veccia, Enzo Galligioni	0
12	Weekly paclitaxel (wPCT) for pretreated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Updated data from a single institution experience in the daily clinical practice. 2014 ·Journal of Clinical Oncology ·(unknown), Orazio Caffo, Viviana Murgia, Antonello Veccia, S. Brugnara, A. Caldara, Antonella Ferro, M. Frisinghelli, Francesca Maines, Lucianna Russo, (unknown), F. Valduga, Enzo Galligioni	0
13	Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors 2012 ·Urology ·Orazio Caffo, Giovanni Pappagallo, S. Brugnara, A. Caldara, (unknown), Antonella Ferro, M. Frisinghelli, Viviana Murgia, Lucianna Russo, (unknown), F. Valduga, Antonello Veccia, Enzo Galligioni	42
14	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens 2011 ·British Journal of Cancer ·(unknown), Vanna Chiarion‐Sileni, Michele Guida, Laura Ridolfi, Antonella Romanini, Paola Del Bianco, Jacopo Pigozzo, S. Brugnara, Giuseppe Colucci, Ruggero Ridolfi, Gian Luca De Salvo	45
15	Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study 2008 ·Journal of Clinical Oncology ·Vanna Chiarion‐Sileni, Michele Guida, Ruggero Ridolfi, Antonella Romanini, S. Brugnara, Paola Del Bianco, (unknown), Rossana Cavallo, Jacopo Pigozzo, Davide María Donati, Gian Luca De Salvo	2
16	M‐CAM expression as marker of poor prognosis in epithelial ovarian cancer 2006 ·International Journal of Cancer ·D Aldovini, Francesca Demichelis, Claudio Doglioni, Dolores Di Vizio, Enzo Galligioni, S. Brugnara, (unknown), C. Griso, (unknown), (unknown), Manuela Gariboldi, Emanuela Balladore, Delia Mezzanzanica, Silvana Canevari, Mattia Barbareschi	75
17	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial 2002 ·Journal of Clinical Oncology ·Ruggero Ridolfi, Vanna Chiarion‐Sileni, Michele Guida, Antonella Romanini, Roberto Labianca, Andrea Freschi, Re G, Rolando Nortilli, S. Brugnara, (unknown), Oriana Nanni	54
18	Pain after quadrantectomy and radiotherapy (QUART) for early-stage breast cancer (BC): incidence, characteristics and influence on quality of life (QL). Results from a retrospective study 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Maurizio Amichetti, Orazio Caffo, S. Brugnara, F. Valduga, Enzo Galligioni	1
19	Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer 2000 ·Breast Cancer Research and Treatment ·Orazio Caffo, (unknown), (unknown), (unknown), (unknown), Maurizio Amichetti, Daniela Bernardi, S. Brugnara, (unknown), A. Lucenti, (unknown), (unknown), Claudio Eccher, Enzo Galligioni	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact